Wikidata

(Q27853079)

English

A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.

scientific article

In more languages

Statements

title
A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma (English)
1 reference
stated in
Europe PubMed Central
PubMed ID
25294897
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25294897%20AND%20SRC:MED&resulttype=core&format=json
retrieved
20 February 2020
main subject
patient
0 references
author name string

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q27853079&oldid=1119417912"